A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
Status:
Terminated
Trial end date:
2017-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities,
and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.